Management of the acute respiratory distress syndrome

Alexandre T. Rotta,1 Cláudia L. Kunrath,2 Budi Wiryawan3

Abstract

Objective: To review the current support and treatment strategies of the acute respiratory distress syndrome.

Sources of data: Original data from our research laboratory and from representative scientific articles on acute respiratory distress syndrome and acute lung injury searched through Medline.

Summary of the findings: Despite advances in the understanding of the pathogenesis of acute respiratory distress syndrome, this syndrome still results in significant morbidity and mortality. Mechanical ventilation, the main therapeutic modality for acute respiratory distress syndrome, is no longer considered simply a support modality, but a therapy capable of influencing the course of the disease. New ventilation strategies, such as high-frequency oscillatory ventilation appear to be promising. This text reviews the current knowledge of acute respiratory distress syndrome management, including conventional and non-conventional ventilation, the use of surfactant, nitric oxide, modulators of inflammation, extracorporeal membrane oxygenation and prone position.

Conclusions: The last decade was marked by significant advances, such as the concept of protective ventilation for acute respiratory distress syndrome. The benefit of alternative strategies, such as high-frequency oscillatory ventilation, the use of surfactant and immunomodulators continue to be the target of study.


Introduction

Acute respiratory distress syndrome (ARDS) is an entity marked by a significant inflammatory response to a local (pulmonary) or remote (systemic) insult which invariably results in hypoxemia and marked alterations to pulmonary mechanics. By definition four clinical criteria must be met to establish a diagnosis of ARDS1: 1) Acute disease onset, 2) bilateral pulmonary infiltrates on chest x-ray, 3) pulmonary capillary wedge pressure ≤ 18 mmHg or absence of clinical evidence of left atrial hypertension, and 4) ratio between arterial oxygen partial pressure (PaO2) and the fraction of inspired oxygen (FiO2) ≤ 200. Patients that meet criteria 1 to 3, but exhibit a PaO2 / FiO2 ratio >200 and ≤ 300 are defined as having Acute Lung Injury (ALI), a process physiopathologically similar to ARDS but of lesser clinical severity. Based on the above criteria, it is estimated that
ARDS has an incidence of 13.5 cases per 100,000 people and that ALI affects 17.9 of every 100,000 people. Despite significant advances in general intensive care therapies, the dramatic alterations that are characteristic of ARDS are associated with an elevated mortality, varying between 35% and 71%. Despite having first been described several decades ago and being a significant cause of morbidity and mortality in pediatric intensive care units all over the world, ARDS has no specific pharmacological treatment. However, advances in the understanding of the pathogenesis and pathophysiology of ARDS over the years have resulted in the development of a series of support therapies capable of having an impact on the outcome of patients affected by this pathology (Table 1).

**Table 1 - Therapeutic Strategies in ARDS**

<table>
<thead>
<tr>
<th>Control of the causative factor (sepsis, shock, etc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanical Ventilation</td>
</tr>
<tr>
<td>- Controlled oxygen exposure</td>
</tr>
<tr>
<td>- Avoidance of volutrauma (using reduced tidal volumes)</td>
</tr>
<tr>
<td>- Avoidance of atelectrauma (using adequate PEEP)</td>
</tr>
<tr>
<td>Careful fluid administration</td>
</tr>
<tr>
<td>Optimization of hemodynamics and tissue oxygen delivery</td>
</tr>
<tr>
<td>Non-conventional ventilation</td>
</tr>
<tr>
<td>- High-frequency ventilation</td>
</tr>
<tr>
<td>- Ventilação não invasiva</td>
</tr>
<tr>
<td>- Liquid ventilation</td>
</tr>
<tr>
<td>Drug-based therapies</td>
</tr>
<tr>
<td>- Surfactant</td>
</tr>
<tr>
<td>- Nitric oxide</td>
</tr>
<tr>
<td>- Corticosteroids and other anti-inflammatory agents</td>
</tr>
<tr>
<td>Extracorporeal membrane oxygenation (ECMO)</td>
</tr>
<tr>
<td>Position therapy (proning)</td>
</tr>
<tr>
<td>Prevention and early diagnosis of intercurrent infections</td>
</tr>
<tr>
<td>Analgesia and sedation</td>
</tr>
<tr>
<td>Nutritional support</td>
</tr>
<tr>
<td>Psychological support (patient and family)</td>
</tr>
</tbody>
</table>

Despite having been successful in an experimental laboratory environment, many of the methods available for the management of ARDS have not been shown effective or have not yet been properly tested in clinical practice. This is primarily due to the fact that patients with ARDS form an extremely heterogeneous population, who needs to be evaluated in studies of large samples, requiring significant resources and a large capacity for integration among participating centers. The availability of clinical data specific to the pediatric ARDS population is even more limited due to the almost non-existence of controlled studies in this population. This being the case, many of the strategies employed for the management of pediatric ARDS and their indications have been adapted or inferred from studies of adult patients.

**ARDS treatment strategies**

*Control of the causative factor*

While ARDS has no specific treatment, many of the factors causing and perpetuating the disease process can be treated or controlled. For example, patients with hypovolemic shock should be quickly identified and treated with rapid volumetric replacement, in order to minimize the impact on the evolution and maintenance of ARDS. Similarly, patients with infectious acute abdomen should be treated with antibiotics and early surgical intervention when indicated. Patients with septic shock or pneumonia that evolve to ARDS should be promptly treated with intravascular expansion and antibiotics, since the treatment of the infectious factor and hemodynamic control are fundamental to the success of managing the subsequent pulmonary pathology.

*Controlled oxygen exposure*

By definition, patients with ARDS exhibit significant hypoxemia ($\text{PaO}_2/\text{FiO}_2 < 200$). For this reason, oxygen is indicated for the management of the initial phase of the acute respiratory insufficiency. Severe hypoxemia in patients with ARDS is due to the intrapulmonary shunt, in which unventilated lung zones that result from edema, atelectasis or consolidation continue to receive blood supply, despite being incapable of participating in its oxygenation. Oxygen therapy, via mask, tent or non-invasive ventilation apparatus is capable of producing symptomatic improvement during the initial phase of acute respiratory failure. However, the rapid natural progression of ARDS with diminishing pulmonary compliance, increased exertion of respiratory muscles and subsequent exhaustion means that oxygen therapy only has value as a temporary symptom relief measure until mechanical ventilation is introduced. The great majority of patients that meet diagnostic criteria for ARDS cannot be managed exclusively with oxygen therapy, and will require mechanical ventilation. The health care professional who understands the pathophysiologic process of ARDS should recognize that a patient that meets diagnostic criteria and requires an accelerated escalation in oxygen therapy will need mechanical ventilation. Oxygen therapy should not delay the institution of ventilatory support, since intubation and initiation of mechanical ventilation for ARDS should be an elective decision made before the patient develops full-blown respiratory failure.
The administration of oxygen, while simple, is not free from adverse effects. Continuous exposure to high concentrations of oxygen (FiO₂ > 0.6) is capable of causing pulmonary injury, even in the absence of a pre-existing lesion. Pulmonary injury due to oxygen toxicity is the result of free radicals and reactive oxygen species that are spontaneously generated in hyperoxic environments or from the activation of neutrophils and alveolar macrophages. The normal lung deals with oxidative insults by means of a series of enzymes (superoxide dismutase, glutathione peroxidase, glutathione reductase, catalase) or antioxidants (vitamins C and E, albumin, etc.), and is capable of tolerating elevated oxygen concentrations for a number of days. However, an injured lung exposed to moderate concentrations of oxygen (which would not be harmful to a normal lung) can further aggravate pulmonary tissue damage even when the exposure is limited to just a few hours. This phenomenon occurs, presumably, due to an imbalance between oxidative stimuli and antioxidant protective mechanisms found in acute lung injury states.

**Mechanical ventilation**

Mechanical ventilation remains the primary support technique for ARDS and is indicated in the vast majority of cases. Nonetheless, the indications for mechanical ventilation in patients with ARDS are, to a certain extent, vague, based on clinical findings (dyspnea, tachypnea, use and fatigue of accessory muscles, diaphoresis, poor perfusion, etc.), laboratory findings (acidosis, hypoxemia, hypercapnia) and radiological findings (worsening alveolar infiltrates). An attempt at making the criteria for the institution of mechanical ventilation for ARDS more objective is the so-called “rule of 50s”, in which a PaO₂ < 50 torr and a PaCO₂ > 50 torr with a FiO₂ of 50% characterize patients likely to require ventilatory support. These criteria, however, identify patients in extremely severe disease states with impending respiratory failure. One of the key points in the treatment of ARDS is the early identification of patients with respiratory involvement so that mechanical ventilation can be initiated before they reach an extreme state of respiratory failure.

The heterogeneous distribution of lung disease in patients with ARDS makes mechanical ventilation a challenge to the intensive care specialist. In typical ARDS, gravitationally-dependent lung regions exhibit dense alveolar and interstitial inflammatory infiltrates, edema, cellular debris, atelectasis and consolidation, while non-dependant regions are relatively spared (Figure 1). In a healthy lung with homogeneous surface tension, tidal volume is evenly distributed among the various lung segments. In patients with ARDS, however, the tidal volume follows the path of least impediment, with a tendency to overdistend the more compliant alveoli (non-dependent) while failing to recruit the less compliant alveoli in the dependent areas. In addition to being heterogeneous, lung pathology in ARDS is also dynamic, as areas with relatively adequate compliance can become poorly compliant in a matter of hours, as the syndrome evolves rapidly.

Mechanical ventilation for ARDS is much more than a mere support modality used to buy time until resolution of the lung disease process. We now know that the choice of ventilation strategy is capable of influencing the progression of the lung disease, with more favorable outcomes resulting from protective strategies. Similarly, non-protective ventilation strategies are associated with less favorable physiological outcomes and increased mortality.

**Figure 1** - a) Computerized axial tomography of an experimental ARDS model (swine) showing the heterogeneous distribution of lung disease. The gravitationally non-dependent lung region (white arrow) exhibits a relatively normal aspect, while the dependent lung region (black arrow) exhibits greater involvement. Histologic analysis of another animal model of ARDS (rabbits) also shows the heterogeneous distribution of this pathology, with less evidence of inflammation and tissue injury in the non-dependent region (b) in contrast with the dependent region (c). The use of an objective pulmonary injury score in this same model (d) confirms the heterogeneous distribution of tissue injury.
**Tidal volume (Vt)**

The use of an inadequately high Vt in experimental models is capable of promoting pulmonary injury even in healthy lungs. In experimental ARDS models, a Vt that has traditionally been considered adequate, such as 10 ml/kg, has been associated with progression and worsening of the pulmonary injury. This occurs because, in low pulmonary compliance states, the introduction of moderate or high Vt can lead to alveolar overdistension, marked by the upper inflection point on the volume-static pressure relationship curve (Figure 2), resulting in the so-called “volutrauma”. Based on this principle, Amato and colleagues have demonstrated significantly reduced 28-day mortality in ARDS patients treated with an open lung strategy consisting of a Vt of less than 6 ml/kg and PEEP set above the lower inflection point. However, two other studies, employing reduced Vt only failed to show any benefit from this strategy in patients with ARDS. More recently, a North American multi-center study involving 861 patients with ARDS showed a 22% reduction in mortality among patients treated with reduced Vt (6 ml/kg) in comparison with traditional Vt (12 ml/kg). The discrepancies between results of the various multi-center studies are related to significant methodologic variations, such as different Vt values employed for the intervention and control groups (Figure 3). Only studies with a sufficient difference in Vt between the reduced volume and the control groups yielded positive results.

To this date, no clinical studies have tested the hypothesis that reduced Vt would be beneficial in the pediatric population. However, considering that the recommendation to use reduced Vt has a strong physiological, experimental and clinical support (in adults), pediatric patients with ARDS should be given mechanical ventilation with a Vt equal to or less than 6 ml/kg until data specific to this population become available.

**Positive end-expiratory pressure (PEEP)**

In ARDS, alveoli in the dependent lung regions exhibit greatly reduced compliance in comparison with non-dependent alveoli. As such, during every expiration the more dependent alveoli reach a critical closing volume, which results in alveolar collapse. This is followed by reopening of these collapsed alveoli during inspiration. The cyclical repetition of alveolar collapse and re-opening generates shearing forces capable of causing tissue damage (atelectrauma). The use PEEP is primarily aimed at avoiding the collapse of the less compliant alveoli at the end of expiration. Excessive use of PEEP increases the risk of pneumothorax, generates hyperinflation of certain pulmonary segments and can cause adverse hemodynamic effects by increasing intra-thoracic pressure and thus reducing venous return (pre-load). However, the application of inadequately low PEEP levels during mechanical ventilation provokes cyclic alveolar collapse and re-opening, resulting in atelectrauma.

The use of adequate levels of PEEP that target sufficient lung volume maintenance during is associated with favorable physiological outcomes. As has been mentioned above, Amato and colleagues have demonstrated a reduction in 28-day mortality in patients ventilated with a Vt lower than 6 ml/kg and PEEP level set above the lower inflection point. It is impossible to discern whether the observed effects are attributable to the limited Vt, the use...
of sufficient PEEP or both (Figure 3). However, strategies that apply sufficient PEEP while avoiding alveolar overdistension can prevent the generation of pro-inflammatory mediators (biotrauma) that may adversely affect the progression of the pulmonary lesion, as well as damage remote organs if these substances were to enter into circulation. Despite the protective role of PEEP having been systematically documented in laboratory studies, the North American multi-center clinical trial of patients treated with a high pulmonary expiratory volume and low FiO2 compared with patients treated with a low pulmonary expiratory volume and high FiO2 was recently terminated due to futility after the inclusion of 550 patients.

**Ventilation mode**

Modern conventional mechanical ventilators offer an increasing array of ventilation modes for use in patients with ARDS. Conceptually, however, most ventilation modes used in ARDS are similar in that they are cycled by time and limited by volume or pressure. A mode that is cycled by time and limited by volume implies that the cycle (inspiration and expiration) is controlled by time (inspiratory time and breath rate), and that during the inspiratory phase of the cycle a certain pre-determined volume is administered. A mode that is cycled by time and limited by pressure implies that the cycle (inspiration and expiration) is controlled by time (inspiratory time and breath rate), and that during the inspiratory phase of the cycle a certain pre-determined pressure is administered. In volume-limited ventilation, the Vt administered during each inspiration generates a certain airway pressure (which is measured and controlled in current ventilators). Similarly, in pressure-limited ventilation, the application of a specific pressure gradient between the ventilator and the airway results in the generation of a certain Vt that can be measured and controlled. Regardless of the ventilation mode used, it is important to emphasize that no one conventional ventilation mode has been shown to be clinically superior to another in the management of patients with ARDS, as long as the principles of protective ventilation are respected.

Considering that precise Vt control is a very important factor in ARDS support, time-cycled volume-limited modes are preferred by the most of intensive care specialists nowadays. In time-cycled volume-limited ventilation (controlled, assist-controlled, intermittent mandatory or intermittent mandatory with pressure support) the operator defines the exact Vt to be administered by each mandatory ventilator cycle. The pressure measurements generated by this set volume at the end of inspiration (dynamic) or after a pause (static or plateau pressure) are indicators of pulmonary compliance in ARDS. A peak inspiratory pressure which increases over time for a fixed volume generally indicates worsening compliance. In an analogous manner, a reduction in peak inspiratory pressure generally indicates an improvement in compliance. Volume-limited ventilation traditionally generates a triangular pressure waveform, in contrast with the rectangular waveform of pressure-limited ventilation (Figure 4). As the area under the pressure curve reflects mean airway pressure, volume-limited modes (triangular waveforms) generally have a slightly lower mean airway pressure than pressure-limited modes (rectangular waveform). Modern ventilators like the Servo 300, however, offer a mode known as pressure regulated volume control (PRVC), in which the shape of the pressure waveform of this volume-limited mode is similar to the rectangular format of the pressure-limited mode. As such,
the use of PRVC has been gaining wide acceptance in the management of patients with ARDS.

**Fluid administration**

In caring for patients with ARDS, the intensive care specialist must ponder the quantity and quality of fluids that will be administered. For rapid intravascular expansion, the decision on the administration of colloids or crystalloids depends, to a certain extent, more on the personal convictions of the individual intensive care specialist than on established scientific facts. Those who prefer to give colloids justify the practice by the fact that these substances are capable of producing greater intravascular expansion per unit of volume, remain longer within the intravascular space and increase colloid osmotic pressure. Those who choose crystalloids do so because these are cheaper, more readily available, are capable of promoting intravascular expansion equivalent to colloids (when infused volumes are adjusted) and because they do not increase oncotic pressure in the pulmonary interstitium should they extravasate from the capillaries, as can occur with colloids. Controlled clinical studies are inconclusive on the superiority of colloids or crystalloids. Therefore, the choice of fluids for rapid intravascular expansion should be based on the patient’s needs at any given moment, taking into account the type of loss that has occurred, the urgency to resuscitate and the availability of fluids, in addition to plasma colloid osmotic pressure.

The amount of fluids administered to patients with ARDS is also the subject of debate. There is no question that patients in shock or with severe hypovolemia, both risk factors for ARDS, should be aggressively resuscitated, generally with infused volumes that exceed 60 ml/kg during the first hour, since this practice reduces mortality and is not associated with an increased incidence of ARDS. Once hemodynamic stability is achieved in the patient with ARDS, the intensive care specialist should concentrate efforts on minimizing the capillary leak and pulmonary edema accumulation that occur in ARDS. Studies in animal models of acute lung injury indicate that the fluid accumulation in the lung can be attenuated by reducing left atrial pressure. This strategy of limiting fluid administration is also supported by some clinical studies of patients with ARDS. The North American study group involving 24 hospitals (ARDS Network) organized for the study of ARDS is currently conducting a controlled multi-center, randomized study of “conservative” versus “liberal” fluid administration. Until the results of this study become available, a sensible recommendation is to maintain intravascular volume at the lowest level that permits the maintenance of adequate systemic perfusion, assessed by renal and cardiac functions and by the acid-base balance.

**Non-conventional ventilation**

**High frequency ventilation (HFV)**

Mechanical ventilation techniques that employ supraphysiologic frequencies, generally between 60 and 900 cycles per minute, are collectively known as HFV. Various types of HFV are available, although only high frequency positive pressure ventilation (HFPPV), high frequency jet ventilation (HFJV) and high frequency oscillatory ventilation (HFOF) have gained significant penetration into clinical practice. Clinical studies of HFPPV and HFJV compared with conventional ventilation were disappointing and resulted in the virtual abandonment of these techniques for the management of patients with ARDS. The use of
HFOV, however, is strongly supported by studies of experimental ARDS models, and has sufficient clinical evidence to justify its use under selected circumstances.

In HFOV, tidal volumes that approximate dead space volume are actively pushed into and pulled out of the airway at a frequency of between 3 and 15 hertz (180 to 900 cycles per minute) by means of a piston or diaphragm. The proposed advantage of HFOV is that, due to the minute tidal volume of each cycle, the method is capable of ventilating patients with ARDS within a “Safety Zone” that avoids both alveolar overinflation during inspiration and cyclical closure and re-opening of the alveoli during expiration (Figure 2). Oxygenation and ventilation are controlled independently during HFOV. Controlling the mean airway pressure determines the state of pulmonary inflation and, consequently, oxygenation. Controlling the amplitude of oscillation indirectly determines the tidal volume of each cycle and, consequently, the efficacy of ventilation (CO₂ elimination). As such, HFOV is ideal in situations when the patient with ARDS has worsening pulmonary compliance with hypoxemia, requiring a reduction in the Vt of conventional ventilation in order to avoid elevated peak inspiratory pressures, which leads to significant respiratory acidosis. The realization that HFOV can favorably influence the pulmonary inflammatory milieu in experimental models as well as reduce the incidence of chronic lung disease has been responsible for the enthusiasm about this method and for its increasingly early deployment in patients with ARDS. The use of HFOV in pediatric patients with ARDS requires deep sedation and neuromuscular relaxation, since spontaneous respiratory movements interfere with gas flow mechanics in this modality.

Non-invasive ventilation

The application of non-invasive positive pressure (CPAP or BiPAP) in patients with ARDS is capable of attenuating, albeit temporarily, the reduction in residual functional capacity responsible for the progressive hypoxemia that is characteristic of this pathology. The use of CPAP results in a transient improvement in oxygenation, yet it is not associated with reductions in the need for intubation, length of hospital stay or mortality of patients with ARDS. The use of CPAP for ARDS is also associated with an increased incidence of adverse effects. As such, the use of CPAP in the prophylaxis or treatment of patients with ARDS is not recommended.

Partial liquid ventilation

Partial liquid ventilation (PLV) is a technique that employs perfluorochemical substances capable of dissolving large quantities of oxygen and carbon dioxide. In PLV, the lung is filled with a liquid perfluorocarbon via the endotracheal route so as to occupy the functional residual capacity, while volumes of gas are introduced through a conventional ventilator during each inspiratory cycle. The potential advantage of PLV in ARDS stems from the fact that when the lung is occupied by liquid it has a uniform surface tension, in contrast to the heterogeneous surface tension typical of ARDS. This occurs because the perfluorocarbon forms a liquid-liquid interface at the alveolar surface, in contrast to the liquid-gas interface found in conventional ventilation. A medical-grade perfluorocarbon called perflubron (C8-F17-Br1) has been successfully tested in the treatment of experimental acute lung injury. We now know that perflubron, as well as other perfluorocarbons that were considered biologically inert, have anti-inflammatory biological effects and protect cellular components against oxidative damage. However, the enthusiasm for PLV in the laboratory has not been repeated in the clinical arena. Controlled studies of children and adults with ARDS and acute lung injury have not demonstrated PLV to be superior to protective conventional ventilation. Further studies are necessary to test the impact of this method in specific clinical situations, such as progressive pulmonary recruitment (liquid PEEP) and intrapulmonary drug administration or viral vectors for genetic therapy. This treatment is not currently available for use outside of the research laboratory environment and cannot be recommended for the treatment of ARDS.

Drug-based therapies

Surfactant replacement

The success of surfactant therapy with premature newborns, associated with the fact that the surfactant system is dysfunctional in patients with ARDS, led intensive care specialists to speculate on a possible role for this substance in the treatment of this syndrome. However, the use of surfactant in adult patients has not been shown effective at improving oxygenation, shortening duration of mechanical ventilation or reducing mortality in a controlled clinical study. Possible explanations for this include the administration method employed (aerosol), which results in less than 5% of the dose, as well as the type of surfactant used (a phospholipid preparation without surfactant proteins). New surfactant preparations extracted from bovine lungs that contain phospholipids, neutral lipids and hydrophobic surfactant proteins types B and C are considered to be more effective and are being tested in patients with ARDS for administration via endotracheal tube. Until definitive studies are available, the routine use of surfactants in patients with ARDS cannot be recommended, being reserved for non-routine use in special situations when recruitment of lung segments cannot be achieved with more conventional methods. Even in these situations, the use of surfactants in ARDS is questionable.
Nitric oxide

Nitric oxide is a potent vasodilator that can be administered via inhalation causing pulmonary vascular relaxation. Inhaled nitric oxide reaches the alveolus where it enters into direct contact with the pulmonary vasculature. During its migration through the wall of the blood vessel, nitric oxide causes direct relaxation of the muscular layer, before reaching the vascular lumen. Nitric oxide is then rapidly deactivated by binding with hemoglobin, resulting in the formation of methemoglobin and avoiding the undesirable effect of systemic vasodilatation. The pulmonary vasodilatory effect of nitric oxide associated with the fact that the target vasculature is adjacent to the ventilated areas of the lung results in not only a decrease in pulmonary vascular resistance, but also in attenuation of ventilation-perfusion mismatch, thus improving oxygenation. The use of nitric oxide in newborns with pulmonary hypertension has achieved great clinical success, reducing morbidity and the need for extracorporeal support. However, its use in patients with ARDS has been disappointing. Despite producing a transient improvement in oxygenation, this benefit is of short duration and does not offer any objective gains. The use of nitric oxide in ARDS does not reduce mortality or the duration of mechanical ventilation and cannot therefore be routinely recommended in clinical practice. Nitric oxide can be used as a therapy of exception for temporary rescue of patients with hypoxemia that is refractory to more conventional interventions.

Corticosteroids

The fact that acute pulmonary damage in ARDS is primarily the result of an aggressive inflammatory process has lead intensive care specialists to consider anti-inflammatory agents in general, and corticosteroids in particular, as logical therapeutic alternatives. The use of corticosteroids, however, does not prevent the development of ARDS nor is it beneficial when employed during the initial phase of its clinical course. Corticosteroids appear to have some benefit when used during the later stages of the disease, which are marked by the reorganization of the acute inflammatory infiltration and fibrosing alveolitis. Currently, a multi-center randomized controlled North American study (ARDS Network) is being conducted to evaluate the efficacy of high doses of methylprednisolone during the later phases of ARDS. However, due to the fact that treatment with high doses of corticosteroids can increase the risk of secondary infections and other adverse effects, their routine use in ARDS treatment cannot yet be recommended. In our clinical practice, we reserve the use of corticosteroids as a rescue therapy in severe ARDS cases during the later phase of the disease (third or fourth week) when there is no progress in reducing the level of ventilatory support.

Other inflammation control agents

Despite having produced promising results in experimental models of acute lung injury, the use of non-steroidal drugs with anti-inflammatory effects, such as indomethacin, ibuprofen, procysteine, lisofylline and ketoconazole, have not been shown beneficial in the clinical arena. The use of these drugs for the treatment of patients with ARDS, therefore, cannot be recommended.

Extracorporeal membrane oxygenation (ECMO)

Extracorporeal membrane oxygenation consists of the use of a complex circuit of vascular cannulae, tubes, pumps, oxygenator, heat exchanger and monitoring systems used to provide respiratory support (in the case of veno-venous ECMO) or cardiorespiratory support (in the case of veno-arterial ECMO). To date, approximately 22,000 patients have undergone ECMO throughout the world with an overall survival rate of approximately 75%. The vast majority of these patients are neonates with refractory pulmonary hypertension, while the experience in pediatric and adult cases of ECMO for treatment of ARDS is limited to approximately 3,000 cases (personal communication, ECMO Registry of the Extracorporeal Life Support Organization (ELSO), Ann Arbor, Michigan, November, 2002). Extracorporeal membrane oxygenation reduces the mortality of newborns with persistent pulmonary hypertension secondary to meconium aspiration syndrome (94% survival), but has yielded more modest results in older children with ARDS (52% survival). Clinical studies of the use of ECMO or an extracorporeal carbon dioxide elimination system with adults suffering from ARDS did not reveal any benefits in terms of reduced mortality. However, the outcome results for ECMO therapy in the international extracorporeal life support registry for pediatric patients with ARDS refractory to all other forms of treatment, and also in our personal practice, strongly suggest that this technique is of value in selected cases.

Indications for ECMO in ARDS cases are restricted to patients with the highest degree of acute pulmonary failure that is potentially reversible, yet unresponsive to all less invasive conventional or non-conventional treatment methods. The basic premise for indicating ECMO is that the death of the patient is presumably imminent without the use of this technology. During the last 7 years, 22 of these pediatric patients with extreme respiratory failure underwent ECMO for treatment of ARDS at the Children’s Hospital of Buffalo, with a survival rate of 54%. These results are compatible with those from other centers of excellence in North America and are a great impediment to the realization of randomized trials. In common with us, the majority of centers that utilize this treatment method consider unethical to allocate patients who are candidates for ECMO to a control group without intervention, since such patients have a projected mortality rate of nearly 100%.
**Positioning therapy**

The simplicity and low cost of the use of prone positioning, associated with reports of improvements in oxygenation in 60 to 70% of patients with ARDS has made this therapeutic method popular. A number of different mechanisms have been suggested to explain this effect in patients placed in the prone position, such as an improvement in the ventilation-perfusion relationship, increased pulmonary volume at the end of expiration and regional ventilation changes associated with mechanical alterations of the thoracic wall. However, as has been demonstrated above, improvements in oxygenation do not necessarily translate to reduced mortality in ARDS. Recently,Gattinoni and colleagues reported the results of a multi-center, controlled study in which patients with ARDS were randomized to receive either conventional treatment (supine position) or treatment in the prone position for 6 or more hours per day for 10 days. In this study, despite causing an improvement in oxygenation, the use of the prone position did not result in a reduction in mortality. A number of different theories may explain these findings. The simplest is that the use of the prone position indeed does not prevent or attenuate the advance of pulmonary injury in patients with ARDS. On the other hand, despite including 304 patients, this study probably did not have sufficient statistical power to reveal differences between groups, since clinical studies of ARDS are marked by heterogeneous characteristics demanding large sample sizes. The patients randomized to the prone group assumed the position for approximately 7 hours per day (or just 30% of the time) and for a maximum of 10 days. It is possible that the limited duration of exposure to the prone position could explain the failure of this strategy.

A multi-center study of pediatric patients with ARDS involving the use of the prone position for the greater part of the day and until resolution of the respiratory failure is in progress in tertiary ICUs in North America. Until concrete results are available, the recommendation to place patients with ARDS in the prone position in an attempt to improve oxygenation and allow exposure to lower concentrations of oxygen appears to have a reasonable theoretical foundation and few risks or costs associated with it.

**Prevention and early diagnosis of intercurrent infections**

As ARDS patients require invasive technology, such as vascular and urinary catheters, endotracheal intubation and mechanical ventilation for prolonged periods of time, they are often the target of secondary infections, especially pulmonary infections. Early diagnosis and precise treatment of these infections is extremely important, since secondary pneumonias act as an additional pro-inflammatory insult. Radiologic diagnosis of secondary pulmonary infections in patients with ARDS is complicated by the fact that these patients exhibit pre-existing radiologic abnormalities. Clinical diagnosis also presents challenges, since symptoms such as fever, leukocytosis and increased tracheal secretions may already be part of the basic disease process. In clinical practice, early diagnosis may be achieved by integrating radiologic alterations, appearance and cellularity of tracheal secretions and routine cultures (tracheal aspirate, broncho-alveolar lavage and blood culture).

As with other nosocomial infections, prevention is the best method of reducing the risk of secondary pulmonary infections. Immunosuppressed or contagious patients should be isolated and the use of universal contact precautions and frequent hand washing are simple and highly effective measures. Criteria-based antibiotic therapy guided by the antibiogram of organisms isolated by cultures or on local epidemiological data also plays an important role in the prevention of secondary infections.

**Analgesia and sedation**

The comfort of patients with ARDS during their stay in the ICU should occupy a prominent position in the therapeutic strategy. Patients in the acute phase of the disease should receive infusions of medications to reduce the emotional stress and physical discomfort inherent to the pathology, as well as in anticipation of painful procedures. Our practice is to maintain patients with ARDS on continuous sedation and pain relief, with these needs being reevaluated on a daily basis. Infusions of midazolam (0.1 mg/kg/h) and fentanyl (2 µg/kg/h) are used in the majority of patients and doses are adjusted according to clinical requirements, with doses of 10 times higher than the original not being uncommon by the third week of the clinical course. Patients subjected to permissive hypercapnia or HFOV require the infusion of neuromuscular blocking agents, such as vecuronium (0.1 mg/kg/h). Patients with highly compromised pulmonary mechanics and during the acute phase of the disease also often require neuromuscular blocking agents.

**Nutritional Support**

Patients with ARDS have an elevated daily caloric requirement as a function of the stress of trauma, sepsis, surgery or the inflammatory process that accompanies the lung injury in ARDS. These patients require prompt institution of parenteral or enteral nutrition since a caloric deficit can result in alterations of the defense mechanisms, as well as delay lung healing. We prefer continuous enteral nutrition via the naso-duodenal route, as soon as technically feasible. Total parenteral nutrition should be started immediately for patients who demonstrate intolerance or contraindications to enteral nutrition. Among potential complications of parenteral nutrition, it should be noted that hypercapnia can occur as the result of an excessive carbohydrate load through alterations in the respiratory quotient.
Psychological support

The psycho-social needs of the family and the patient with ARDS are extremely complex. Even in adequately sedated patients, factors such as anxiety over the uncertainty of the clinical outcome, the impossibility of speech due to the artificial airway, the occasional pain due to invasive procedures and the changes to the awake and sleep cycles, among others, cannot be neglected by the medical team. Attention must be afforded to explain to the patient (whenever possible) and the family all the diagnostic and therapeutic procedures and also the natural course and prognosis of the condition. It is common for adolescent patients and older children in the recovery phase of ARDS to exhibit delirium, depression or altered circadian patterns during prolonged hospitalization in an ICU environment. Such manifestations often require the involvement of a psychiatric consultant to monitor patients during recovery and after hospital discharge. The multidisciplinary medical team should always be alert to and available for the psychological needs of ARDS patients and their families, particularly because ICU hospital stays due to severe ARDS are prolonged and generally marked by oscillation between periods of frustration and optimism.

Monitoring the patient

Patients with ARDS represent a relatively severe stratum of the population of a tertiary ICU. As such, these patients require a high level of monitoring so that data can be obtained and integrated in real time for individual strategic treatment planning. Patients with ARDS routinely require an arterial catheter for continuous arterial pressure monitoring and for obtaining serial arterial blood gas analysis. A central venous catheter with two or three lumens is used for the administration of fluids and drugs and also for continuous measurement of the central venous pressure. A urinary catheter permits the precise measurement of urinary output and control of the fluid balance. Continuous pulse oximetry is used for real time assessment of oxygenation. Analysis of exhaled carbon dioxide curves provides a continuous data for inferring ventilation, pulmonary perfusion and dead space. Respiratory monitoring via graphic interfaces allows for the real time visualization of a series of respiratory parameters derived from pressure, flow, time and volume. Serial echocardiography is a good method for monitoring the degree of atrial filling (preload) as well as the cardiac function resulting form different combinations of inotropic drugs and states of intravascular expansion. In our experience, a pulmonary artery catheter (Swan-Ganz) has little use in patients with ARDS with no primary cardiac involvement. The use of such catheters rarely alters the management based on data obtained from the auxiliary technologies described above. Patients requiring continuous neuromuscular blockade should be monitored with nerve stimulators to avoid the unnecessary use of exaggerated drug doses.

References

33. Derdak S, Mehta S, Stewart TE, Smith T, Rogers M, Buchman
32. Arnold JH, Hanson JH, Toro-Figuero LO, Gutierrez J, Berens
31. Wiswell TE, Graziani LJ, Kornhauser MS, Cullen J, Merton DA,
30. Humphrey H, Hall J, Sznajder I, Silverstein M, Wood L. Improved
29. Prewitt RM, McCarthy J, Wood LD. Treatment of acute low
28. Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation
27. Carvalho CR, Barbas CS, Medeiros DM, Magaldi RB, Lorenzi
26. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS. Injurious
25. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS. Injurious
24. Stover TE, Meade MO, Cook DJ, Granton JT, Hodder RV,
23. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
22. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
20. Ranieri VM, Giunta F, Suter PM, Slutsky AS. Mechanical
19. Wiswell TE, Graziani LJ, Kornhauser MS, Cullen J, Merton DA,
18. Brochard L, Roudot-Thoraval F, Roupie E, Delclaux C, Chastre
17. Stewart TE, Meade MO, Cook DJ, Granton JT, Hodder RV,
16. Wiswell TE, Graziani LJ, Kornhauser MS, Cullen J, Merton DA,
15. Feihl F, Perret C. Permissive hypercapnia. How permissive
14. Willson DF, Zaritsky A, Bauman LA, Dockery K, James RL,
12. Anzueto A, Baughman RP, Estes RJ, Wunderink RG, el Torky
11. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
10. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
8. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
7. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
6. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
5. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
4. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
3. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
2. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn
1. Rotta AT, Gunnarsson B, Hernan LJ, Fuhrman BP, Steinhorn

